A patient with recurrent urothelial carcinoma of the bladder with POLE p.E277Q mutation achieved a complete response with an anti–PD-1 antibody and had no disease progression for over 3 years (Data Supplement, Fig S5). This evidence concerns the gene POLE and bladder transitional cell carcinoma.